01/06/2016

ESTEVE SIGNS AN AGREEMENT WITH ASTRAZENECA TO MARKET (TYPE 2 DIABETES DRUGS) EDISTRIDE AND EBYMECT IN SPAIN

ESTEVE has reached an agreement with AstraZeneca to market -in Spain and as of this month of June- the drugs Edistride (dapagliflozin) and Ebymect (dapagliflozin and metformin) for the treatment of type 2 diabetes in adult patients. This alliance further extends Esteve's commitment in this therapeutic area.

Edistride is an oral antidiabetic drug indicated as monotherapy in patients intolerant of metformin. Its active ingredient, dapagliflozin, reduces the absorption of glucose filtered in the kidney, thus resulting in urinary glucose excretion and further decreasing blood glucose levels in plasma.
Ebymect is another oral antidiabetic drug that combines dapagliflozin and metformin and can be used in patients not properly controlled with the maximum tolerated dose of metformin in monotherapy, or in patients already treated with the dapagliflozin/metformin combination in separate tablets.
Both medicines can be used in combination with other hypoglycemic drugs, including insulin, when these, together with diet and exercise, fail to properly control blood sugar levels.
"Our agreement with ESTEVE clearly reflects our commitment with Spain and with national partners. We are convinced that their wide expertise in the Spanish market, their knowledge of this area and the passion for science we share will continue to improve the quality of life of diabetic patients", states Rodrigo Gribble, Director of the Cardiometabolism Business Unit of AstraZeneca Spain.
For his part, ESTEVE Farma's Managing Director Joe Sullivan declares that "the alliance with AstraZeneca allows to continue offering the most innovative treatments of diabetes to both professionals and patients. It will also further strengthen our activities in this therapeutic area -a priority of the company".

Diabetes is a chronic disease that occurs when the pancreas fails to produce sufficient amounts of insulin or when the body cannot use the insulin it produces effectively. According to the 2015 atlas of the International Diabetes Federation, it currently affects 415 million people worldwide and is estimated to have been the direct cause of more than 5 million deaths. In Spain, the prevalence of type 2 diabetes mellitus is higher than 5 million adults, of which more than 2 million go undiagnosed, according to data from the Spanish Diabetes Association.

You can follow ESTEVE on Twitter at this link:
twitter.com/esteve_news.

Related Information

Last news

  • THE PROGRAM ’PLAN PROFARMA’ HAS ONCE AGAIN QUALIFIED ESTEVE’S R&D&I AS ’’EXCELLENT’’

    Once again, ESTEVE's research activity has received the qualification ''Excellent'' in the Program 'Plan Profarma' (Program for Fostering Scientific Research, Technological Development and Innovation ...

    read more
  • PENSA PHARMA HAS BEEN AWARDED A PRIZE FOR ITS BEST DEVELOPMENT AND COMMERCIALIZATION OF GENERIC MEDICINES

    Pensa Pharma (PENSA), a company of the ESTEVE Group specialized in generic medicines, has been awarded a prize at the II edition of La Razón Comunidad Valenciana Awards. Specifically, PENSA has receiv...

    read more
  • ESTEVE APPOINTS THOMAS B. RIISAGER AS CHIEF CORPORATE STRATEGY & BUSINESS DEVELOPMENT OFFICER

    ESTEVE has announced today the appointment of Thomas B Riisager as Chief Corporate Strategy & Business Development Officer, to be heading Corporate Strategy & Business Development for the pharmaceutic...

    read more

Follow us at

This Website uses its own and third-party cookies to improve our services and analyse the user's browsing habits. If you continue browsing, we will consider you to have accepted their use. You can find more information by visiting our Cookies policy.